Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News CEL-SCI Corp CVM

Healthcare Biotechnology
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:CVM)

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Business Wire November 7, 2024

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Business Wire October 22, 2024

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

Business Wire October 1, 2024

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Business Wire September 16, 2024

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

Business Wire September 10, 2024

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

Business Wire September 4, 2024

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

Business Wire August 15, 2024

CEL-SCI Announces Closing of $10.8 Million Offering

Business Wire July 29, 2024

CEL-SCI Announces Pricing of $10.8 Million Offering

Business Wire July 26, 2024
View More News ››

Opinion & Analysis (NYSEAM:CVM)

Alternative, green energy stock picks

J.W. Cotton December 2, 2009

Stock picks with insider buying

J.W. Cotton November 20, 2008

Dividend and speculative stock picks

J.W. Cotton October 28, 2008
View More Opinion ››

Bullboard Posts (NYSEAM:CVM)

Great coverage on CVM

    https://youtu.be/fAg5VUkO5T0
BryceCanada - September 16, 2024

CEL-SCI Corporation (CVM): Pioneering Immunotherapy for Head

http://beyondspx.com/2024/08/02/cel-sci-corporation-cvm-pioneering-immunotherapy-for-head-and-neck-cancer-with-promising-phase-3-results/
MikeTester - August 3, 2024

BUY BUY BUY BUY BUY

To the moon at 4$and back
Nibinator - July 26, 2024

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of

JUST IN: $CVM CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck CancerCritical...
whytestocks - May 8, 2024

Excellent YT coverage out on CVM

https://youtu.be/YssziKz9Us0?si=pt2yEe4GGZIAd9Oz
BryceCanada - May 7, 2024

Why CEL-SCI Corporation (CVM) Shares Are Diving | Benzinga

Breaking News: $CVM Why CEL-SCI Corporation (CVM) Shares Are Diving | BenzingaCEL-SCI Corporation (NASDAQ:CVM) shares are trading lower...
whytestocks - February 9, 2024
View more Bullboard ››

Lancaster Resources Inc.

Lancaster Resources Inc.

Lancaster Resources Inc. is a Canada-based company engaged in exploring lithium and uranium and other critical minerals. The ...
View More »